Xinjiang Easy Diagnosis Biomedicine Co.,Ltd. announced that it expects to receive CNY 5 million in funding from Wuhan Easy Diagnosis Biomedicine Co.,Ltd. and another investor
June 29, 2020
Share
Xinjiang Easy Diagnosis Biomedicine Co.,Ltd. announced that it will receive CNY 5 million in a round of funding on June 30, 2020. The transaction will include participation from returning investor, Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (SZSE:002932) for CNY 2.55 million, to retain its 51% stake in the company and Wang Wanxin for CNY 2.45 million. The transaction is subject to approval of the Chairman of Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (SZSE:002932). Post the completion of the transaction, the registered capital of the company will increase from CNY 5 million to CNY 10 million.
Wuhan Easy Diagnosis Biomedicine Co., Ltd. is a China-based company which is mainly engaged in research and development, manufacture and sales of Point of Care Testing (POCT) rapid diagnostic reagents and quick testing instruments. The Company's main products are POCT rapid diagnostic reagents, which can be divided into six categories: infectious diseases, cardiovascular and cerebrovascular diseases, kidney diseases, diabetes, gynecology and eugenics, and health checkups. The Company's main products are mainly used in domestic hospitals, health service centers, community clinics, medical examination centers and other medical institutions.
Xinjiang Easy Diagnosis Biomedicine Co.,Ltd. announced that it expects to receive CNY 5 million in funding from Wuhan Easy Diagnosis Biomedicine Co.,Ltd. and another investor
WUHAN EASY DIAGNOSIS BIOMEDICINE CO.,LTD. 
